<DOC>
	<DOCNO>NCT02063958</DOCNO>
	<brief_summary>Study design determine maximum tolerate dose ( MTD ) SNX-5422 give combination everolimus .</brief_summary>
	<brief_title>Safety Pharmacology SNX-5422 Plus Everolimus Subjects With Neuroendocrine Tumors</brief_title>
	<detailed_description>Heat shock protein 90 ( Hsp90 ) play central role maturation maintenance numerous protein , example HER2 mutate EGFR , critical tumor cell viability growth ; SNX-5422 pro-drug SNX-2112 , potent , highly selective , small-molecule inhibitor molecular chaperone heat shock protein 90 ( Hsp90 ) . Hsp90 find express 95 % subject pancreatic neuroendocrine tumor . This study determine MTD SNX-5422 give combination everolimus patient neuroendocrine tumors.The clinical start dose 50 mg/m2 qod SNX-5422 combination daily everolimus 50 % SNX-5422 qod mono-therapy MTD . The choice continue every day SNX-5422 dosing base safety efficacy profile prior study , drug holiday intersperse weekly dosing . The planned subsequent dose level 75 % 100 % SNX-5422 qod mono-therapy MTD .</detailed_description>
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Males nonpregnant , nonbreastfeeding female 18 yearsofage old . Archived neuroendocrine tumor sample biopsy sample ( also use genetic testing ) . Pathologic evidence chemoresistant Small Cell Lung cancer ( relapse &lt; 90 day 1st line ) , chemosensitive Small Cell Lung Cancer ( relapse &gt; 90 day first line ) , locally advanced metastatic neuroendocrine tumor gastroentero , pancreatic , pulmonary ( Small Cell Lung ) thymic origin , advance renal cell carcinoma everolimus indicate . Measurable ( RECIST ) indicator lesion previously irradiate . Life expectancy least 3 month . No 4 prior line systemic anticancer therapy . Karnofsky performance score ≥70 . Adequate baseline laboratory assessment , include Absolute neutrophil count ( ANC ) ≥1.5 x 109/L . WBC &gt; 3000/microliter Platelet count ≥100 x 109/L . Total bilirubin level ≤1.5 time institutional upper limit normal ( ULN ) , alanine aminotransferase aspartate aminotransferase ≤2 x ULN Hemoglobin ≥9 mg/dL . Creatinine &lt; 1.5 X upper limit normal estimate plasma creatinine clearance ≥40 mL/min Signed informed consent form Recovered toxicities previous anticancer therapy Subjects reproductive capability must agree practice adequate contraception method . Subjects everolimus contraindicate . Subjects clinically significant interstitial lung disease , obstructive disease without sufficient reserve Carcinoid hormone relate symptom Neuroendocrine cancer thyroid thymus . Rare pancreatic neuroendocrine cancer , insulinomas , glucagonomas , gastrinomas . Prior treatment Hsp90 inhibitor . Prior fail treatment mTOR inhibitor CNS metastases symptomatic /or require escalate dos steroid . Major surgery significant traumatic injury within 4 week start study treatment . Conventional chemotherapy radiation within 4 week . Palliative radiation within 2 week . The need treatment medication clinicallyrelevant metabolism cytochrome P450 ( CYP ) 3A4 isoenzyme within 3 hour administration SNX5422 Screening ECG QTc interval ≥470 msec female , ≥450 msec male . At increase risk develop prolonged QT interval , include hypokalemia hypomagnesemia , unless correct within normal limit prior first dose SNX5422 ; congenital long QT syndrome history torsade de pointes ; currently receive antiarrhythmic medication may associate QT prolongation . Patients chronic diarrhea Grade 2 great diarrhea despite appropriate medical management . Gastrointestinal disease condition could affect drug absorption , include gastric bypass . Gastrointestinal disease could alter assessment safety , include irritable bowel syndrome , ulcerative colitis , Crohn 's disease , hemorrhagic coloproctitis . History document adrenal dysfunction due malignancy . Known seropositive human immunodeficiency virus ( HIV ) hepatitis C virus ( HCV ) . History chronic liver disease . Active hepatitis A B . Current alcohol dependence drug abuse . Use investigational treatment 30 day prior first dose SNX5422 study . Glaucoma , retinitis pigmentosa , macular degeneration , retinal change detect ophthalmological examination . Other serious concurrent illness medical condition . Psychological , social , familial , geographical reason would hinder prevent compliance requirement protocol compromise inform consent process .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Neuroendocrine tumor</keyword>
	<keyword>Hsp90</keyword>
</DOC>